CASTRATION-RESISTANT PROSTATE CANCER (CRPC)
Clinical trials for CASTRATION-RESISTANT PROSTATE CANCER (CRPC) explained in plain language.
Never miss a new study
Get alerted when new CASTRATION-RESISTANT PROSTATE CANCER (CRPC) trials appear
Sign up with your email to follow new studies for CASTRATION-RESISTANT PROSTATE CANCER (CRPC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug IDE574 enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called IDE574 in people with advanced solid tumors or a specific type of breast cancer (ER+, HER2-). The drug targets two enzymes that help cancer cells grow. The study has two parts: first, testing IDE574 alone in various cancers; second, combining it…
Matched conditions: CASTRATION-RESISTANT PROSTATE CANCER (CRPC)
Phase: PHASE1 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Radioactive antibody targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called 177LuBetaBart in people with advanced solid tumors that have stopped responding to standard treatments. The drug is a radioactive antibody designed to seek out and destroy cancer cells. The study will enroll about 61 participants and…
Matched conditions: CASTRATION-RESISTANT PROSTATE CANCER (CRPC)
Phase: PHASE1, PHASE2 • Sponsor: Radiopharm Theranostics, Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC